Aspirin and Preeclampsia
Aspirin to Prevent Cardiac Dysfunction in Preeclampsia
University of Chicago
180 participants
Feb 15, 2021
INTERVENTIONAL
Conditions
Summary
This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.
Eligibility
Inclusion Criteria3
- Pregnant Adults between 18 and 45 years of age
- Diagnosed with preeclampsia
- Presenting for delivery with a singleton gestation.
Exclusion Criteria9
- We will exclude patients in labor
- Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation
- Plan to deliver outside of the participating site
- Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI.
- Aspirin allergy
- Clear indication for aspirin therapy or contraindication to aspirin therapy
- Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)
- Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study.
- Those who cannot provide consent
Interventions
Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04479072